Pura Vida Investments LLC bought a new stake in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 70,000 shares of the company’s stock, valued at approximately $1,329,000. Pura Vida Investments LLC owned 0.21% of Deciphera Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $143,000. FNY Managed Accounts LLC acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $153,000. Sphera Funds Management LTD. acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $1,424,000. Perceptive Advisors LLC acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $1,946,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Deciphera Pharmaceuticals in the 3rd quarter valued at approximately $1,968,000. Hedge funds and other institutional investors own 43.94% of the company’s stock.

Several research firms recently commented on DCPH. Nomura began coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock. Instinet initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $57.00 price target on the stock. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “outperform” rating and a $38.00 price target on the stock. Finally, J P Morgan Chase & Co initiated coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set an “overweight” rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $43.40.

Deciphera Pharmaceuticals Inc (DCPH) opened at $17.82 on Thursday. Deciphera Pharmaceuticals Inc has a 1 year low of $16.11 and a 1 year high of $24.50.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($5.30). analysts forecast that Deciphera Pharmaceuticals Inc will post -2.91 EPS for the current year.

In other news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ILLEGAL ACTIVITY NOTICE: “70,000 Shares in Deciphera Pharmaceuticals Inc (DCPH) Acquired by Pura Vida Investments LLC” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/70000-shares-in-deciphera-pharmaceuticals-inc-dcph-acquired-by-pura-vida-investments-llc/1762841.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.